Team:BIT/nb
Journal
March :
i. Strength:
1. Convenience.
2. Adaptability.
3. High Cost/Performance Ratio.
4. Inelastic to change in test conditions.
ii. Weakness:
1. Technology Barrier.
2. Branding Barrier.
3. Strict Market Admittance Criteria.
4. Distribution Barrier.
iii. Opportunity:
1. Favorable national economic condition.
2. Positive national policies.
3. Uprising Health-consciousness.
iv. Threats:
1. Well-established industries control the high-end markets with related products.
2. Industrial chain is currently complete
3. Technological applications are matured
b. Comments:
Comparing to technology equipped by clinics and hospitals, The use of adjustable aptamer and genetic modified microbes made JACOB more economical, adaptable, and stable. The integration of automated proceeding made JACOB more user-friendly and portable. JACOB does not need professional physicians reading results, behaving like glucose meter but less risky. In China it is likely to be deployed in units of household or local communities. Similarly, for United States the Food and Drug Administration classified the core mechanism of JACOB as Class I medical device (if designed to not detecting cancer biomarkers), means no premarketing control is required. It is worth noting though, Chinese in vitro diagnostic market is relatively new and have few competitors. Those few players can no longer support the concrete increasing demand for medical cares. Chinese government had ratified a great number of acts as well as guidelines and simplified documents examining and approval process to encourage innovation in the field of medical devices, which offers our team a great market environment.
Hire Us!
Facilis ipsum reprehenderit nemo molestias. Aut cum mollitia reprehenderit. Eos cumque dicta adipisci architecto culpa amet.
